Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | -0.24 | -3.19 | 1.28 |
| FCF Yield | -0.85% | -1.70% | -1.04% | -0.55% |
| EV / EBITDA | -42.27 | -42.01 | -46.34 | -92.43 |
| Quality | ||||
| ROIC | -3.53% | -4.46% | -3.37% | -2.78% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 112.19% |
| Cash Conversion Ratio | 0.53 | 0.70 | 0.72 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.70% | -61.62% | 0.96% | 7.13% |
| Free Cash Flow Growth | 46.68% | -39.61% | -3.75% | -643.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.73 | 0.91 | 1.47 | 14.30 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -578.43 | -407.69 | -764.59 |